Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EHP-101
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The purpose of the study was to examine the effects of EHP-101 on cardiac and other organ fibrosis induced by angiotensin II, which is implicated in the progression of myocardial fibrosis.
Brand Name : EHP-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 02, 2021
Lead Product(s) : EHP-101
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EHP-101, a novel product candidate with a unique multi-modal mechanism of action, has demonstrated disease-modifying potential in validated preclinical models of multiple sclerosis.
Brand Name : EHP-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 08, 2021
Lead Product(s) : EHP-101
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EHP is currently initiating a Phase 2 clinical study for systemic sclerosis in Australia, New Zealand and the United States with EHP-101.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 03, 2020
Lead Product(s) : EHP-101
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?